Table 2.

Effect of the IRF5 risk haplotype on the expression of gene sets. Gene set enrichment analysis showed gene sets enriched in the risk haplotypes of either SLE-unaffected controls or SLE patients without EBV infection. Genes shown have a false discovery rate (FDR) of <25%.

Gene set name	Affected pathways or cellular conditions	No. of genes	Normalized enrichment score	P value	FDR q-value
Unaffected controls
CROONQUIST_IL6_STROMA_UP	IL-6 exposure	37	−2.026	0.0018	0.038
PASSERINI_INFLAMMATION	Inflammation	23	−1.751	0.0112	0.212
PASSERINI_PROLIFERATION	Proliferation	62	−1.782	<0.0001	0.224
ADIP_DIFF_CLUSTER2	Differentiation	41	−1.752	0.004	0.225
CROONQUIST_RAS_STROMA_DN	Ras activation	21	−1.757	0.0038	0.229
UVB_NHEK3_C6	UV light exposure	27	−1.763	0.0039	0.234
HOHENKIRK_MONOCYTE_DEND_DN	Dendritic cell maturation	121	−1.724	0.0348	0.239
LEE_DENA_UP	Murine liver cancer	59	−1.769	<0.0001	0.241
ZUCCHI_EPITHELIAL_DN	Breast cancer metastasis	44	−1.785	0.0117	0.245
SLE patients
IFNALPHA_HCC_UP	IFNα	29	−1.968	0.0038	0.042
IFNALPHA_NL_HCC_UP	IFNα	18	−1.878	0.0096	0.063
RADAEVA_IFNA_UP	IFNα	49	−1.897	0.0059	0.07
IFNALPHA_NL_UP	IFNα	27	−1.847	0.0099	0.075
BENNETT_SLE_UP	SLE	28	−1.785	0.0082	0.138